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ABSTRACT
Between June and November 2004, a vancomycin-resistant Enterococcus faecium (VRE) strain was isolated
from 13 patients in the haematology ⁄ bone marrow transplant unit. There were difficulties in identifying
the organism,which had low-level, inducible vancomycin resistance, and standard screeningmethods did
not reveal carriage in patients or their contacts. These technical failures led to spread of VRE and delays in
providing appropriate management, which might otherwise have been avoided. Therefore, we reviewed
our laboratorymethods and compared three identification systems todeterminewhichwouldbest identify
this VRE strain. The VITEK 2 (BioMerieux) correctly identified, as E. faecium, only two of 16 isolates,
whereas API Rapid ID 32 Strep (BioMerieux) and Phoenix 100 (Becton Dickinson and Co.) correctly
identified 13 of 15 and 12 of 13 isolates tested, respectively. Isolates from urine, tested by the CLSI disk
diffusion method, were apparently susceptible or of intermediate susceptibility to vancomycin, upon
primary testing. VITEK 2 and Phoenix 100 identified all isolates as vancomycin-resistant, although the
MICs, measured by Etest, were in the susceptible range for three of 16 isolates. Reducing the vancomycin
concentration in screeningmedia substantially increased the sensitivity for detection of VRE. Isolateswere
characterized as genotype vanB2 ⁄ 3 by PCR andwere indistinguishable from each other by pulsed-field gel
electrophoresis. VRE with low-level inducible resistance can be missed by routine screening methods.
Better identification and screeningmethods for detection of low-level vancomycin resistance are needed to
improve surveillance and prevent transmission of VRE.
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INTRODUCTION
Enterococci are important nosocomial pathogens,
and can cause significant morbidity and mortality
in hospitalized patients [1]. Nosocomial transmis-
sion of vancomycin-resistant Enterococcus faecium
(VRE) with moderate- to high-level resistance to
vancomycin in haematology patients is well
described [2–4]. E. faecium with low-level induc-
ible vancomycin resistance has also been
described as causing hospital outbreaks, but
infrequently [5]. In Australia, VRE isolates were
first detected in 1994 [6], and since then several
sporadic and outbreak-related strains have been
reported in patients from most Australian states
[7–10]. The majority have been of the vanB
genotype with moderate - to high-level resistance
to vancomycin (64–256 mg ⁄ L), but E. faecium
carrying vanA has also been reported [11,12].
VRE strains with the vanB phenotype were orig-
inally described as having inducible low-level
resistance to vancomycin but not teicoplanin [13].
However, glycopeptide-resistant enterococci car-
rying vanB are considered to be phenotypically
diverse, and typically show a wide range of
vancomycin MICs, usually with moderate- to
high-level resistance (64–1024 mg ⁄ L) [14].
Although clinical laboratories can reliably detect
high-level resistance to vancomycin, there are
reports of poor proficiency in the detection of low-
level inducible resistance to vancomycin [15–17].
Several problems associated with screening,
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identification and susceptibility testing of a strain
of E. faecium with low-level inducible vancomycin
resistance and modifications to overcome them
are described here.
METHODS
Patients and bacterial isolates
Westmead Hospital is a tertiary-referral hospital, providing
care for patients in the greater western Sydney area; it includes
a 23-bed haematology ⁄ bone marrow transplant (BMT) unit.
In June–July 2004, vancomycin-resistant Gram-positive cocci,
identified as E. faecium, were isolated from blood cultures of
two patients in the haematology ⁄ BMT unit. Both patients had
been treated with vancomycin for apparently susceptible
enterococcal urinary tract infections immediately prior to
developing bloodstream infections with VRE. This led to
initiation of screening of all patients in the unit upon
admission and weekly thereafter.
Identification of enterococci in blood and urine
Isolates obtained from blood cultures were identified to genus
level by Gram staining, L-pyrrolindonyl-b-naphthylamide
reaction, catalase reaction, and streptococcal grouping
(Phadebact Strep D Test, Boule Diagnostics AB, Huddinge,
Sweden). At the time of this outbreak, identification to species
level and susceptibility testing were performed using the auto-
matedVITEK 2 system(BioMe´rieuxVITEKInc.,Hazelwood,MI,
USA). If this failed to provide definite identification, the API
Rapid ID 32 Strep system (BioMe´rieux, Marcy l’Etoile, France)
was used, according to the manufacturer’s recommendations.
Isolates from urine were presumptively identified using
chromogenic agar [18] (CHROMagar Orientation, Paris,
France). Gram-positive cocci, which appeared as dark blue
colonies on chromogenic agar, were reported as ‘group D
streptococci’ if they were susceptible to ampicillin and vanco-
mycin. They were identified to species level, as for blood
culture isolates, if they were ampicillin-resistant or not fully
susceptible to vancomycin.
Susceptibility testing
Susceptibilities to ampicillin, erythromycin, tetracycline, cip-
rofloxacin, high-level gentamicin, vancomycin and teicoplanin
were determined using the VITEK 2 Gram-positive suscepti-
bility card. For isolates that were not fully susceptible to
vancomycin, the MICs of vancomycin and teicoplanin were
determined by Etest (AB Biodisk, Solna, Sweden), using the
high-inoculum method on Mueller–Hinton agar, according to
the manufacturer’s recommendations [19,20]. For urine iso-
lates, antibiotic susceptibility testing was performed by disk
diffusion, as recommended by the CLSI [21], and if not fully
susceptible to vancomycin, MICs were determined by Etest.
Screening of patients for intestinal carriage of VRE
Perianal swabs were collected from all patients in the haema-
tology ⁄ BMT unit, and inoculated into Todd–Hewitt broth and
chromogenic agar, both supplemented with gentamicin and
vancomycin. After 24 h of incubation, the Todd–Hewitt broths
were subcultured onto non-selective chromogenic agar to
assist in the detection of enterococci. The concentration of
vancomycin used, initially, was 5.4 mg ⁄ L, or slightly less than
the concentration (6 mg ⁄ L) recommended by the CLSI, based
on local experience. Subsequently, the vancomycin concentra-
tion was reduced, when VRE screening of patients with proven
VRE infections was persistently negative. The final vancomy-
cin concentration was 4.3 mg ⁄ L. This allowed growth of the
E. faecium strain involved in this outbreak, while preventing
excessive overgrowth of other bacteria.
Further comparative testing of stored isolates
All bloodstream isolates are routinely stored in our laboratory,
and those from the outbreak were retrieved for further testing.
Urine isolates from the first two patients involved in this
outbreak and one of the perianal isolates were not available for
retesting. Thirteen stored VRE isolates were available for
retesting. Species identification was attempted, using three
methods: VITEK 2, the API Rapid ID 32 Strep system and
Phoenix 100 (BD Phoenix Automated Microbiology System,
Becton Dickinson and Co., Sparks, MD, USA), which was
under evaluation in our laboratory at the time. They were also
tested for susceptibility to vancomycin using VITEK 2,
Phoenix 100 and Etest as described above.
Susceptibility to ampicillin, erythromycin, tetracycline,
ciprofloxacin, gentamicin (high-level resistance) and teicopla-
nin was tested by VITEK 2 on all stored isolates.
Where multiple isolates were obtained from a single
episode of infection or from repeated perianal swabs, only
one was fully characterized. If isolates were obtained from
different sites, then one isolate from each site was fully
characterized.
Molecular testing
Vancomycin resistance genotypes were identified using the
LightCycler VRE detection kit according to the manufac-
turer’s instructions (Roche Diagnostics, Penzberg, Germany).
This kit provides the primers and hybridization probes for
the amplification and detection of vanA, vanB and vanB2 ⁄ 3.
Briefly, a 232-bp fragment of vanA and a 187-bp fragment of
vanB were amplified by PCR from DNA extracted from
colonies grown on horse blood agar. Each test run included
a water blank as negative control and the positive control
from the kit, which contained specific sequences of the vanA
and vanB gene targets. All reactions included an internal
control of plasmid DNA that acts as an extraction and
inhibition control. Confirmation of the resistance genotype
was determined by melt curve analysis using the Roche
LightCycler. VanA and vanB genotypes display characteristic
melting (Tm) peaks at 67 ± 2.5C and 60 ± 2.5C, respec-
tively.
Pulsed-field gel electrophoresis was performed using the
CHEF-Mapper instrument (Bio-Rad Laboratories, Hercules,
CA, USA), following digestion of genomic DNA with the
restriction endonuclease Sma1 (New England Biolabs, Ipswich,
MA, USA). The digested DNA underwent electrophoresis for
20 h at 14C and 6 V ⁄ cm. Switch times were ramped from 0.47
to 21.79 s over the length of the run. Gel analysis was carried
out using BIONUMERICS software (Applied-Maths, Kortrijk,
Belgium). Gel comparison settings were fixed on the Dice
coefficient to produce an unweighted pair group method using
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arithmetic averages (UPMGA) dendrogram with band toler-
ance set at 1.5%. The percentage optimization was set at 0%
for the analysis.
RESULTS
VRE isolates
Between June and November 2004, VRE strains
were isolated from seven infected and six colo-
nized patients, all of whom had been hospitalized
in the haematology ⁄ BMT unit. Among the
patients with infection, the first two identified
had urinary tract infections with enterococci
originally reported as being susceptible to vanco-
mycin. It was only when both patients developed
bloodstream infections, within a few days, that
VRE was identified. In the following 4 months, 11
more patients were found to be infected with or
carrying VRE. Three VRE strains were isolated
from blood, two from urine and the remainder
from perianal screening. Two patients died, one
in association with VRE bacteraemia.
The first positive perianal screen was obtained
from the fourth patient in the outbreak, in
association with a urinary tract infection, and
was detected following a reduction in the con-
centration of vancomycin in the screening media.
Prior to that, all perianal screens had been
negative, even in patients known to have been
infected with VRE. Another six patients were
subsequently found, by perianal screening, to be
colonized with VRE.
The results of screening, identification and
susceptibility testing of 16 isolates from 13
patients, using different methods, are shown in
Table 1.
Identification
Among 13 isolates tested, Phoenix 100 identified
12 isolates as E. faecium, but gave no identification
for one other, on two separate occasions. VITEK 2
identified only two of 16 isolates as E. faecium
(with an acceptable identification score); three
were identified as Aerococcus viridans and there
was no match for the remaining 11. The Rapid
ID 32 Strep system identified all 13 isolates
retrieved from storage as E. faecium (with scores
of 1 or 2 representing good or excellent identifi-
cation, respectively); two isolates from urine,
initially identified as E. gallinarum, were not
available for retesting.
Susceptibility testing
Disk testing, using the CLSI method, was unreli-
able for detection of vancomycin resistance upon
primary isolation. All four isolates from urine and
Table 1. Identification and vancomycin susceptibility testing of vancomycin resistant Enterococcus faecium (VRE) isolates in
a clonal outbreak
Patient no./date Sourcea
Identification results Vancomycin susceptibility results
Screening resultsePhoenix 100b VITEK 2 ID GPC Rapid ID 32 Strepc VITEK 2 MIC CLSI disk Etest 1 ⁄ 2d
1 ⁄ June Urine ND No ID E. gallinarum (3) Rh S 1.5 Negativef 3
Blood E. faecium Aerococcus viridans E. faecium (2) R ND 16 ⁄ 4
2 ⁄ July Urine ND No ID E. gallinarum (3) R S 48 Negativef 4; positive 1
Blood E. faecium A. viridans E. faecium (2) R I 12 ⁄ 32
3 ⁄ August Blood E. faecium No ID E. faecium (2) R ND 48 ⁄ 64 Negativef 2; positive 1
4 ⁄ August Urine E. faecium No ID E. faecium (2) R S 24 ⁄ 32 Negativef 1; positive 2
Perianalg ND E. faecium ND R ND 3
5 ⁄ August Blood No ID No ID E. faecium (2) R ND 256 ⁄ 64 Negative 1; positive 1
6 ⁄ August Perianal E. faecium No ID E. faecium (2) R ND 24 ⁄ 48 Negative 3; positive 1
7 ⁄ August Perianal E. faecium No ID E. faecium (1) R ND 32 ⁄ 32 Positive 1
8 ⁄ August Perianal E. faecium No ID E. faecium (1) R ND ND ⁄ 256 Negative 5; positive 1
9 ⁄ August Perianal E. faecium No ID E. faecium (1) R ND 32 ⁄ 64 Negative 1, positive 6
10 ⁄ September Perianal E. faecium No ID E. faecium (1) R ND 16 ⁄ 64 Negative 1; positive 1
11 ⁄ September Urine E. faecium A. viridans E. faecium (1) R I 64 ⁄ 256 Negative 1
12 ⁄ September Blood E. faecium No ID E. faecium (2) R ND 96 ⁄ 256 ND
13 ⁄ November Perianal E. faecium E. faecium E. faecium (1) R ND 32 ⁄ 96 Negative 2; positive 1
ND, not done; R, resistant; S, susceptible; I, intermediate.
aPerianal isolates were from screening swabs.
bResults were obtained from stored isolates only.
cNumbers in parentheses are scores for phenotypic identifications: 1, excellent or very good identification; 2, good identification; 3, uncertain identification to the species level.
dResults of first and second Etests. The second Etest result was obtained from stored isolates only.
eScreening by perianal swab on media containing 4.3 mg ⁄ L vancomycin.
fScreening by perianal swab on media containing 5.4 mg ⁄ L vancomycin.
gFirst isolate of VRE identified by perianal screening.
hResistant to vancomycin, MIC ‡32 mg ⁄ L[21].
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one from blood were interpreted as vancomycin-
susceptible or vancomycin-intermediate. VITEK 2
and Phoenix 100 labelled all isolates tested as
vancomycin-resistant (MIC ‡32 mg ⁄ L). There
was a wide range of MICs according to Etest,
although the majority were £64 mg ⁄ L, which is
considered to represent low-level resistance. Two
initially, and one upon retesting, had MICs
measured by Etest in the susceptible range
(£4 mg ⁄ L). This variation probably reflects the
inducible nature of vanB and explains why the
level of resistance was below the level of detection
upon primary screening, but became readily
detectable after subculture of these isolates. All
isolates were susceptible to teicoplanin (MIC £8
mg ⁄ L) and high-level gentamicin (MIC £500
mg ⁄ L). All were resistant to ampicillin, tetra-
cycline, erythromycin and ciprofloxacin.
Molecular testing
All 13 isolates tested by PCR, in this study,
contained vanB2 ⁄ 3 (data not shown). These were
compared with each other and three unrelated
E. faecium isolates (from patients in another hos-
pital in Sydney and one from another city) by
pulsed-field gel electrophoresis. The outbreak
isolates were closely related to each other and to
one of the apparently unrelated strains (from
another Sydney hospital), with only minor (one-
or two- band) differences, and easily distinguish-
able from two other unrelated isolates.
DISCUSSION
Clusters of infection or colonization with VRE,
some of which have been reported [9,12,22–25],
have been identified throughout Australia. The
majority are VRE carrying vanB, which was the
genotype identified during this outbreak. Until
this outbreak occurred, only sporadic cases of
VRE colonization or infection, without spread to
other patients, had been identified at the same
hospital. VRE may pose problems with identifi-
cation and susceptibility testing for the clinical
laboratory, particularly when vancomycin resis-
tance is low-level [26,27]. It was found that the
VITEK 2 did not reliably identify E. faecium in
this outbreak, but most isolates were identified
correctly by the API Rapid ID 32 Strep system
and Phoenix 100, both of which appear to be
reliable for identification of enterococci [28].
The detection of low-level, but clinically signif-
icant, vancomycin resistance in enterococci was
particularly problematic in this outbreak. In pub-
lished studies on the identification of vanB VRE,
reported MIC values are typically ‡32 mg ⁄ L
[29,30], and resistance is easily detected, but can
be as low as 8 mg ⁄ L [31]. IsolateswithMICs below
8 mg ⁄ L are generally considered to be susceptible.
However, because vanB is inducible, MIC values
may vary widely in a single outbreak [5].
Vancomycin therapy for urinary tract infections
clearly failed in the two initial patients in this
outbreak, despite the low-level in vitro resistance,
and the patients went on to develop bloodstream
infections. Both were subsequently treated with
teicoplanin, and improved. Two patients died
during the outbreak, one in association with VRE
bacteraemia. The VRE strain was transferred to a
nearby hospital by one of the initial patients, before
the colonization status was recognized, where it
caused a small outbreak in a rehabilitation ward
(data not shown). This emphasizes the problems
that can arise from unrecognized carriage of VRE,
including inappropriate management, increased
patient morbidity and failure to implement appro-
priate infection control measures.
The initial low level of vancomycin resistance
also contributed to difficulties in screening for
VRE carriage. E. faecium carrying vanB2 clearly
has the potential to demonstrate low-level induc-
ible resistance upon primary isolation, which may
be below the recommended detection threshold of
most screening media.
Routine screening and identification methods
were not reliable for the detection of VRE with
low-level inducible resistance in this outbreak,
and modifications to standardized methods had
to be implemented before this outbreak could be
controlled and contained. In the present study,
Phoenix 100 performed best for both identifica-
tion and susceptibility testing of this isolate and
became the method of choice for identifying
enterococci in our laboratory. Screening was
effective only when the concentration of vanco-
mycin was reduced below recommended levels.
Clinical laboratories are generally not proficient at
identifying enterococci with low-level inducible
resistance, and they may be easily missed. When
enterococci are isolated from high-risk patient
groups, a high index of suspicion is required
if outbreaks of VRE with low-level inducible
resistance are to be prevented.
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